Latest in 23andme’s
Sort by
21 items
-
23andMe customer? What to know about the privacy of your genetic data.
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.Top stories - CBS News - 6 hours ago -
What 23andMe business troubles could mean for users' genetic data
The company is laying off 40% of its workforce and discontinuing its therapeutics division.Top stories - ABC News - 6 hours ago -
What to know about 23andMe private data collected amid company's financial issues
The DNA testing company 23andMe is facing serious financial concerns and has announced major restructuring. CBS News MoneyWatch correspondent Kelly O'Grady explains what happens to the private ...Top stories - CBS News - 14 hours ago -
23andMe to lay off 40% of its workforce as stock price plummets
The genetic testing company 23andMe is cutting 40% of its workforce and ending its therapeutics program as its stock price continues to plummet. CBS News correspondent Carter Evans has more on what ...Top stories - CBS News - Yesterday -
What happens to customer data as 23andMe goes out of business?
Millions of people have sent their DNA to be analyzed by 23andMe in order to learn their genealogy and risk for certain health issues. But with the company falling on hard times, and not bound by ...Top stories - CBS News - Yesterday -
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Embattled genetic testing provider 23andMe said Tuesday that revenue declined from a year earlier, a day after the company announced a cost-cutting plan.Business - CNBC - Yesterday -
23andMe’s stock falls after company says there’s substantial doubt it can stay in business
Shares of 23andMe fell 4% Tuesday after the DNA-testing company reported its latest quarterly loss and included “going concern” language in its financial statements, shedding gains made late Monday ...Business - MarketWatch - Yesterday -
23andMe cuts 40% of its workforce and discontinues therapeutics division
23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costsHealth - ABC News - Yesterday -
Genetic testing firm 23andMe cuts 40% of its workforce amid financial struggles
Company says it will cut about 200 employees as value plummets in aftermath of huge data breach. The genetic testing firm 23andMe said on Monday it would cut about 40%, or 200 employees, from its ...World - The Guardian - Yesterday -
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.Business - Inc. - Yesterday -
23andMe warns of ‘substantial doubt’ over its survival without new funding
Once-hyped genetic start-up issues latest guidance after reporting further quarterly revenue declinesBusiness - Financial Times - Yesterday -
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.Business - The Wall Street Journal - 2 days ago -
DNA-testing site 23andMe to lay off 40% of its workers
The once-popular general DNA-testing firm holds a trove of sensitive genetic data from its customers.Top stories - BBC News - 2 days ago -
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.Business - MarketWatch - 2 days ago -
DNA-testing site 23andMe fights for survival
Once millions used it to find out about their family histories - this week it was almost delisted. What went wrong?Top stories - BBC News - November 3 -
23andMe appoints three new board members following abrupt resignations
23andMe appointed three new independent directors to its board, the company said Tuesday.Business - CNBC - October 29 -
Inside the fall of 23andMe
Once worth $6 billion, 23andMe has lost 98% of its value and is on the verge of being delisted from the Nasdaq. So what happened?Business - CNBC - October 23 -
23andMe succumbs to a dismal genetic destiny
Was it nature or nurture? In the unhappy case of a DNA testing company and its sliding share price, the answer is bothBusiness - Financial Times - October 16 -
Founder Anne Wojcicki races to rescue 23andMe
Once-hyped genetic testing company hit by data breach, plunging share price and board resignationsBusiness - Financial Times - October 15